Ensitrelvir Fumaric Acid in Hospitalized Patients with COVID-19 Retrospective Chart Review -Tomita Hospital-

Ensitrelvir Fumaric Acid in Hospitalized Patients with SARS-CoV-2 Retrospective Chart Review -Tomita Hospital- - Ensitrelvir Fumaric Acid in Hospitalized Patients with SARS-CoV-2 Retrospective Chart Review -Tomita Hospital-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051482

Enrollment

Registered

2023-06-30

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are eligible for this study. 1) Patients who received ensitrelvir between November 2022 and April 2023 2) Patients who received ensitrelvir according to the package insert 3) Patients who have all the following required data (1)Start date and end date of ensitrelvir administration (2)SARS-CoV-2 positive test result (3)Clinical symptoms after starting administration of ensitrelvir (4)Outcomes of SARS-CoV-2 infection

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria are excluded from the study. 1) Patients who were treated off-label 2) Patients who refuse to participate in this study

Design outcomes

Primary

Measure	Time frame
Clinical symptoms, oxygen saturation, and food amount at each time point from the start to Day 10 of ensitrelvir administration.	—

Secondary

Measure	Time frame
Outcomes of SARS-CoV-2 infection up to 10 days after the end of administration	—

Countries

Japan

Contacts

Public ContactKentarou Shibata

Shionogi & Co., Ltd. Medical Affairs

kentarou.shibata@shionogi.co.jp03-5219-7310

Outcome results